FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen…
FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and…(PRWeb July 20, 2012)Read the full story at http:/…
FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen… Read Post »
